Somaxon Pharmaceuticals to Update Preclinical Program for SILENOR(TM) for the Treatment of Insomnia and Host Conference Call.SAN DIEGO -- Somaxon Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SOMX) today said that, tomorrow morning, Tuesday, February 13, the company plans to issue a news release, in which it will provide an update on the preclinical program for SILENOR([TM]) (doxepin HCl doxepin HCl, n brand name: Sinequan; drug class: antidepressant, tricyclic; action: inhibits both norepinephrine and serotonin (5-HT) reuptake in synapses in brain; uses: major depression, anxiety. ) for the treatment of insomnia. Additionally, Somaxon management will host a conference call Tuesday morning at 9:00 a.m. Eastern Time to review the preclinical program update. Callers may participate in the conference call by dialing (800) 218-0204 (domestic) or (303) 262-2139 (international). A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international), and entering passcode 11084297#. The conference call also will be available to interested parties through a live audio Internet broadcast at www.somaxon.com and www.opencompany.info. The call will be archived and accessible at both sites for approximately one year. About Somaxon Pharmaceuticals, Inc. Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials phase 3 clinical trial Phase 3 study. See Phase study. for its lead product candidate, SILENOR[TM] (doxepin HCl) for the treatment of insomnia. Somaxon expects to file a New Drug Application with the U.S. Food and Drug Administration for SILENOR[TM] in the third quarter of 2007, assuming that its ongoing preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. proceed as currently scheduled. Somaxon has completed a pilot Phase 2 trial for nalmefene nalmefene /nal·me·fene/ (nal´me-fen?) an opioid antagonist, used as the hydrochloride salt in the treatment of opioid overdose and postoperative opioid depression. in smoking cessation smoking cessation Public health Temporary or permanent halting of habitual cigarette smoking; withdrawal therapies–eg, hypnosis, psychotherapy, group counseling, exposing smokers to Pts with terminal lung CA and nicotine chewing gum are often ineffective. with positive results and a Phase 2/3 clinical trial for nalmefene for the treatment of pathological gambling that did not achieve statistical significance for the primary or secondary endpoints. The company will evaluate the results from both of these trials before making determinations regarding the future of the nalmefene program. Acamprosate Ca, a potential treatment for movement disorders Movement Disorders Definition Movement disorders are a group of diseases and syndromes affecting the ability to produce and control movement. Description , is currently in formulation development. For more information, please visit the company's web site at www.somaxon.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion